GlassScriptPhysician profile
Summer D Waugh
NPI 1437456563
$14,508.56
in general payments reported to CMS, 2019-2025
29 companies · $5,269 in 2025
The $5,269 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $973 · 2022: $1,456 · 2023: $3,817 · 2024: $2,994 · 2025: $5,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,303 · Travel and Lodging: $4,746 · Entertainment: $22.00 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,302.68 |
| Travel and Lodging | $4,746.44 |
| Entertainment | $22.00 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,416.66 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II, Mycarelink |
| Boston Scientific Corporation | $4,208.78 | 2021-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Biosense Webster, INC. | $2,114.62 | 2021-2025 | Carto 3 |
| Abbott Laboratories | $1,740.09 | 2021-2025 | Aveir, Assurity, Navitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $424.41 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $239.59 | 2021-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $213.58 | 2023 | Optimizer |
| Altathera Pharmaceuticals LLC | $156.55 | 2023 | Sotalol Hydrochloride |
| Baxter Healthcare | $141.19 | 2023-2025 | Floseal, Perclot |
| Atricure, INC. | $110.84 | 2023-2024 | |
| Endologix LLC | $101.26 | 2021-2023 | |
| Pfizer INC. | $80.16 | 2021-2024 | |
| Biotronik INC. | $67.75 | 2021-2022 | |
| Stryker Corporation | $56.46 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Artix Mt |
| Smith+Nephew, INC. | $49.44 | 2025 | Pico 14, Versajet |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surmodics, INC. | $47.78 | 2024-2025 | Pounce Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy |
| Cvrx, INC. | $47.04 | 2022-2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $46.82 | 2021-2025 | Camzyos, Eliquis |
| Ossur Americas, INC. | $46.05 | 2025 | |
| Sanofi-Aventis U.S. LLC | $43.59 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $26.12 | 2024 | Giapreza |
| Argentum Medical | $22.00 | 2025 | |
| Kestra Medical Technology Services, INC. | $20.32 | 2025 | Assure Wcd |
| Octapharma USA, INC. | $19.95 | 2024 | Fibryga |
| Biotissue Holdings INC. | $19.71 | 2024 | |
| Angiodynamics, INC. | $16.33 | 2023 | Angiovac |
| Astrazeneca Pharmaceuticals LP | $14.01 | 2021 | |
| Novo Nordisk INC | $12.83 | 2021 | |
| Lifenet Health | $4.63 | 2024 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Waugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.